Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $171→$157 | ― | 35.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $165→$170 | ― | 8.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $204 | ― | 22.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $2.5→$2.25 | ― | 12.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $34→$37 | ― | 10.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $265 | ― | 13.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $325 | ― | 13.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,150→$1,325 | ― | 12.70% | Reiterated | ||||
 | Kosmos Energy | BUY $3.3 | ― | -2.50% | Reiterated | Jefferies Keeps Their Buy Rating on Kosmos Energy (KOS) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $267→$261 | ― | 3.70% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $173→$167 | ― | 3.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $328→$309 | ― | 3.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $40.8→$29 | ― | 6.60% | Downgraded | ||||
 | Archer Daniels Midland | BUY $55→$60 | ― | -1.80% | Upgraded | Positive Report for Archer Daniels Midland (ADM) from UBS | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $1,150→$1,220 | ― | 20.40% | Downgraded | ||||
 | Solventum Corporation | BUY $78→$87 | ― | -6.60% | Upgraded | Promising Growth and Strategic Flexibility: A Buy Recommendation for Solventum Corporation | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $211→$210 | ― | 7.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5→$6 | ― | 7.20% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $88→$98 | ― | 7.20% | Upgraded | ||||
| Nabors Industries | SELL $53→$28 | ― | -1.60% | Downgraded | Nabors Industries downgraded to Underweight from Equal Weight at Barclays | |||
 | Endava | HOLD $18 | ― | -9.30% | Downgraded | Endava downgraded to Neutral from Overweight at JPMorgan | |||
| CI&T | BUY $7 | ― | -9.30% | Upgraded | CI&T upgraded to Overweight from Neutral at JPMorgan | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $5→$3.5 | ― | 4.20% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $67→$105 | ― | 4.40% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17→$25 | ― | 9.60% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $25→$19 | ― | 10.00% | Downgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $168→$115 | ― | 13.30% | Downgraded | ||||
| Biohaven Ltd. | HOLD $54→$21 | ― | -0.50% | Downgraded | Biohaven downgraded to Sector Perform from Outperform at RBC Capital | |||
 | NRX Pharmaceuticals | BUY $18 | ― | -1.00% | Reiterated | NRX Pharmaceuticals: A Promising Investment with Innovative Growth and Strong Financial Outlook | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $450→$550 | ― | 6.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $37→$33 | ― | 1.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $47 | ― | 25.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $351→$364 | ― | 0.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $10 | ― | 0.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $235→$260 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $3,900 | ― | 3.70% | Reiterated | ||||
 | Charter Communications | HOLD | ― | -0.60% | Upgraded | Charter upgraded to Market Perform from Underperform at Raymond James | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 0.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $15 | ― | 13.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $105 | ― | 10.30% | Downgraded | ||||
| UnitedHealth | HOLD $520→$308 | ― | -6.60% | Downgraded | UnitedHealth Hold Rating: Impact of v28 Risk Model, Leadership Changes, and Rising Medical Costs | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $33 | ― | 13.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $101 | ― | 6.10% | Reiterated | ||||
 | Merus | BUY $70 | ― | -5.30% | Reiterated | Promising Outlook for Merus's Petosemtamab in HNSCC Treatment Drives Buy Rating | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $112→$121 | ― | 6.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $129→$128 | ― | 1.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 4.80% | Reiterated | ||||
 | Allegiant Travel Company | HOLD $93→$85 | ― | -1.80% | Reiterated | Allegiant Travel Company: Navigating Capacity Growth Amidst Industry Challenges | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $958 | ― | 2.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $72 | ― | 4.60% | Reiterated |
Rows:
